TNF and psoriasis: To date, five biologic agents targeting TNF-α have been approved for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, IBD, psoriasis, and, most recently, hidradenitissuppurativa [25].